Insmed reported $34.53M in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acelrx Pharmaceuticals ACRX:US $ -597000 68K
Alexion Pharmaceuticals ALXN:US $ 1511.1M 71.5M
Biomarin Pharmaceutical BMRN:US $ 374.63M 8.77M
Dynavax Technologies DVAX:US $ 37.92M 20.79M
Flexion Therapeutics FLXN:US $ 23.2M 4.69M
Gilead Sciences GILD:US $ 4827M 235M
Heron Therapeutics HRTX:US $ 7.92M 2.89M
Insmed INSM:US $ 34.53M 4.16M
Novartis NVS:US $ 9540M 679M
Regeneron Pharmaceuticals REGN:US $ 4444.8M 2224.1M
Sarepta Therapeutics SRPT:US $ 144.57M 19.99M
Seattle Genetics SGEN:US $ 310.39M 42.54M
Ultragenyx Pharmaceutical RARE:US $ 83.84M 10.37M
Vertex Pharmaceuticals VRTX:US $ 1565.4M 33.42M